PE20201405A1 - Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante - Google Patents
Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinanteInfo
- Publication number
- PE20201405A1 PE20201405A1 PE2020001382A PE2020001382A PE20201405A1 PE 20201405 A1 PE20201405 A1 PE 20201405A1 PE 2020001382 A PE2020001382 A PE 2020001382A PE 2020001382 A PE2020001382 A PE 2020001382A PE 20201405 A1 PE20201405 A1 PE 20201405A1
- Authority
- PE
- Peru
- Prior art keywords
- cov
- sars
- recombinant
- salmonella enteritidis
- strain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/42—Salmonella
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invencion se refiere a una vacuna viva recombinante basada en una cepa de Salmonella enteritidis que expresa la proteina S del virus SARS-CoV-2 en donde la mejor expresion se ha logrado cuando la insercion se encuentra en el plasmido en vez del cromosoma. Asimismo, se refiere a una vacuna que precisa de dicha cepa. Tambien se hace referencia al uso de una cepa de Salmonella enteritidis 3934 (depositada en la Coleccion Espanola de Cultivos Tipo (CECT) con el numero de acceso CECT9332) para el tratamiento de SARS-CoV-2 y al metodo para controlar la infeccion por SARS-CoV-2 mediante la administracion a mamiferos de una vacuna viva recombinante
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PE2020001382A PE20201405A1 (es) | 2020-09-09 | 2020-09-09 | Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante |
| PCT/PE2021/000006 WO2022055375A1 (es) | 2020-09-09 | 2021-04-09 | Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PE2020001382A PE20201405A1 (es) | 2020-09-09 | 2020-09-09 | Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20201405A1 true PE20201405A1 (es) | 2020-12-02 |
Family
ID=74205468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020001382A PE20201405A1 (es) | 2020-09-09 | 2020-09-09 | Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante |
Country Status (2)
| Country | Link |
|---|---|
| PE (1) | PE20201405A1 (es) |
| WO (1) | WO2022055375A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20171768A1 (es) * | 2017-06-12 | 2017-12-21 | Farm Veterinarios S A C | Obtencion de una salmonela enteritidis tipo rugosa y sus modificaciones geneticas para uso como vacuna aviar |
-
2020
- 2020-09-09 PE PE2020001382A patent/PE20201405A1/es unknown
-
2021
- 2021-04-09 WO PCT/PE2021/000006 patent/WO2022055375A1/es not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022055375A1 (es) | 2022-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR109538A1 (es) | Vacuna contra la gripe porcina | |
| BR112016003358A2 (pt) | método para aumentar a expressão de proteínas codificadas por rna | |
| CO2019001044A2 (es) | Composición de cannabis | |
| CL2021002582A1 (es) | Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos | |
| EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
| PE20230171A1 (es) | Vacunas contra el coronavirus y metodos de uso | |
| EA202191145A1 (ru) | Вакцина виб 4/91 с гетерологичным шиповидным белком | |
| BR112018075440A2 (pt) | composições e métodos para prevenir e tratar a infecção por zika vírus | |
| AR108829A1 (es) | Vacuna contra virus de bronquitis infecciosa | |
| CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
| CL2021000485A1 (es) | Una cepa mutante de salmonella enteritidis; procedimiento para generar la cepa mutante; vacuna recombinante aviar de salmonella enteritidis, divisional de la solicitud 201903108 | |
| AR041964A1 (es) | Vacuna de vhc que comprende un polinucleotido | |
| CO2022017989A2 (es) | Vacunas para la papilomatosis respiratoria recurrente y métodos para usar estas | |
| DOP2023000053A (es) | Vacuna heteróloga de estímulo primario | |
| CO2022019251A2 (es) | Composiciones y métodos útiles para la prevención y/o el tratamiento de enfermedades en mamíferos | |
| EA202191147A1 (ru) | Вакцина виб h52 с гетерологичным шиповидным белком | |
| AR123244A1 (es) | Vacuna de salmonella para el tratamiento de coronavirus | |
| CL2022000161A1 (es) | Vacuna contra la peste porcina africana | |
| PE20201405A1 (es) | Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante | |
| CO2020004244A2 (es) | Métodos y composiciones para tratar enfermedades pulmonares crónicas | |
| ECSP22064620A (es) | COMPOSICIÓN INMUNOGÉNICA VIVA RECOMBINANTE QUE COMPRENDE EL VIRUS DE LA ENFERMEDAD DE NEWCASTLE (NDV) QUE EXPRESA LA SUBUNIDAD S1 Y EL RBD DE LA PROTEINA SPIKE DEL SARS-CoV-2 | |
| BR112022007474A2 (pt) | Vacina de partículas semelhantes a vírus chikungunya e métodos de uso da mesma | |
| PH12020551944A1 (en) | Reverse peptide vaccine | |
| MX2021003660A (es) | Composicion inyectable. | |
| DOP2014000215A (es) | Virus de la enfermedad de marek modificado y vacunas elaboradas con él |